Positive Topline Results from First-in-Man Trial with CAL02 in the Treatment of Severe Pneumonia

April 17, 2018
Combioxin SA

17 April 2018 – Swiss-based anti-infective company Combioxin SA has announced positive results from the first clinical trial of its novel antibacterial agent CAL02. This novel broad-spectrum liposomal anti-toxin drug was shown to be safe and well tolerated at all dose levels. Consistent and promising efficacy trends were also obtained.


Press Release available here: